JMJD

Choose Selective JMJD Inhibitors

JMJD Products

  • All (8)
  • JMJD Inhibitors (8)
  • New JMJD Products
Catalog No. Product Name Information Product Use Citations Product Validations
S0201 Z-JIB-04 (NSC 693627) Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
S7070 GSK J4 HCl (GSKJ4 HCl) GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.
Nat Immunol, 2022, 23(3):431-445
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
Cell Death Dis, 2022, 13(2):174
S7234 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.
Nat Commun, 2022, 13(1):1172
Chem Biol Drug Des, 2022, 10.1111/cbdd.14051
Sci Rep, 2021, 11(1):2942
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. JIB‑04 also induces cell apoptosis.
mBio, 2022, 13(1):e0337721
Cancer Biol Ther, 2022, 23(1):65-75
Mol Ther Oncolytics, 2021, 20:583-595
S7296 ML324 ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.
Cancer Biol Ther, 2022, 23(1):65-75
Cancer Chemother Pharmacol, 2022, 89(5):643-653
Chem Biol Interact, 2022, 353:109806
S7581 GSK J1 GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
J Biol Chem, 2022, S0021-9258(22)00457-4
Front Cell Dev Biol, 2021, 9:702462
S8287 CPI-455 HCl CPI-455 HCl is a specific KDM5 inhibitor with a half-maximal inhibitory concentration (IC50) of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
Oncogene, 2022, 10.1038/s41388-022-02185-1
Cancers (Basel), 2022, 14(6)1537
S8601 CP2 CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.
Front Cell Dev Biol, 2021, 9:697614
Exp Cell Res, 2021, S0014-4827(21)00315-3
Int Immunopharmacol, 2020, 1;83:106438
S0201 Z-JIB-04 (NSC 693627) Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
S7070 GSK J4 HCl (GSKJ4 HCl) GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.
Nat Immunol, 2022, 23(3):431-445
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
Cell Death Dis, 2022, 13(2):174
S7234 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.
Nat Commun, 2022, 13(1):1172
Chem Biol Drug Des, 2022, 10.1111/cbdd.14051
Sci Rep, 2021, 11(1):2942
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. JIB‑04 also induces cell apoptosis.
mBio, 2022, 13(1):e0337721
Cancer Biol Ther, 2022, 23(1):65-75
Mol Ther Oncolytics, 2021, 20:583-595
S7296 ML324 ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.
Cancer Biol Ther, 2022, 23(1):65-75
Cancer Chemother Pharmacol, 2022, 89(5):643-653
Chem Biol Interact, 2022, 353:109806
S7581 GSK J1 GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
J Biol Chem, 2022, S0021-9258(22)00457-4
Front Cell Dev Biol, 2021, 9:702462
S8287 CPI-455 HCl CPI-455 HCl is a specific KDM5 inhibitor with a half-maximal inhibitory concentration (IC50) of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
Oncogene, 2022, 10.1038/s41388-022-02185-1
Cancers (Basel), 2022, 14(6)1537
S8601 CP2 CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.
Front Cell Dev Biol, 2021, 9:697614
Exp Cell Res, 2021, S0014-4827(21)00315-3
Int Immunopharmacol, 2020, 1;83:106438
Tags: JMJD inhibitor | JMJD modulator | JMJD chemical